

Hansa Medical

- PRESS RELEASE -
March 29, 2017

Top-line clinical results from US study with lead candidate IdeS to be presented at the American Transplant Congress

Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that top-line clinical results from the ongoing investigator initiated US study will be presented in an oral session at the 2017 American Transplant Congress (ATC) in Chicago, U.S. on 30 April. The top-line results from the study, demonstrate that treatment with IdeS completely eliminates donor specific antibodies (DSAs) and enables transplantation of HLA incompatible patients. An abstract with the top-line data and conclusions is available through the ATC website <http://atcmeeting.org>

The abstract, titled *"Experience with The Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Kidney Allograft Recipients"* concludes that: 1. IdeS completely eliminates donor specific antibodies in HLA incompatible patients. 2. IdeS is generally well tolerated with acceptable adverse events and 3. IdeS may provide a more rapid and durable method to desensitize HLA sensitized patients, offering them the benefits of life-saving transplantation. IdeS, IgG degrading enzyme of *Streptococcus pyogenes*, is an enzyme that depletes IgG antibodies fast and effectively. Hansa Medical is developing IdeS as a proprietary treatment to enable kidney transplantation in sensitized patients.

In the US study, 15 highly sensitized patients with mean cPRA 95% received IdeS 4-6 hours prior to incompatible kidney transplantation. The IdeS treatment resulted in total IgG and HLA antibody elimination. Fourteen of 15 patients were successfully transplanted without discernible adverse events. Antibody mediated rejection episodes occurred in four patients and all four responded to anti-rejection treatment. One graft loss occurred due to non-HLA IgM and IgA antibodies. A comparison of the levels of donor specific antibodies before IdeS treatment and one month after IdeS treatment shows a significant reduction.

The abstract supports the company's conviction that IdeS could become the first therapy to enable highly HLA sensitized kidney disease patients to be transplanted. HLA sensitization impacts approximately 30% of patients with kidney disease and is a major barrier to kidney transplantation.

The title, timing and location of the presentations are as follows:

Abstract	#166
Authors:	S Jordan, MD1, J Choi, PharmD1, C Kjellman, PhD2, L Winstedt, PhD2, X Zhang, PhD4, S Louie, MPH1, A Kang, BS1, M Haas, MD, PhD3 and A Vo, PharmD1. 1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States; 2Hansa Medical, Lund, Sweden; 3Dept of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, United States and 4HLA, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Title:	Experience with The Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly HLA Sensitized (HS) Kidney Allograft Recipients
Day/Date:	30 April 2017
Location:	Room E354B
Time:	4.30-6 pm
Session:	Concurrent Session: Novel Immunosuppression – DSA Monitoring
Session Type:	Oral presentations

Hansa Medical

- PRESS RELEASE -
March 29, 2017

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on March 29, 2017 at 10.15 CET.

For further information, please contact:

Hansa Medical AB (Publ)

Emanuel Björne, Vice President Business Development and Investor Relations

Mobile: +46707175477

E-mail: emanuel.bjorne@hansamedical.com

Göran Arvidson, CEO

Mobile: +4670633 3042

E-mail: goran.arvidson@hansamedical.com

www.hansamedical.com

Cord Communications, Stockholm

Mikael Widell

Mobile: +46 70 311 9960

Lars Wahlström

Mobile: +46 73 434 0771

FTI Consulting, London

Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About IdeS

IdeS, IgG degrading enzyme of *Streptococcus pyogenes*, is an enzyme that depletes IgG antibodies fast and effectively. Hansa Medical is developing IdeS as a proprietary treatment to enable kidney transplantation in sensitized patients, previously unable to undergo transplantation surgery due to the presence of anti-HLA IgG antibodies. Top-line efficacy data reported from three phase 2 studies have demonstrated that IdeS rapidly and significantly reduced anti-HLA antibodies, enabling transplantation. IdeS is currently being evaluated in a multi-center study in the U.S. in highly sensitized patients that do not respond to available desensitization methods. Results from this study are expected in 2018. In addition to transplantation, IdeS has potential applications in a variety of rare autoimmune diseases. IdeS is protected by several patents and results of studies with IdeS have been published in a number of peer reviewed scientific journals.

About sensitized patients

Approximately 30 percent of the patients on the waiting lists for kidney, liver, heart, lung and pancreas transplants, equivalent to more than 30,000 patients in Europe, are sensitized to HLAs. HLA sensitization is a risk factor in transplantation meaning that a significant number of sensitized patients are rarely considered for transplantation due to the increased risk of antibody mediated organ rejection.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is a proprietary antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.